Back to top
more

Adaptive Biotechnologies (ADPT)

(Delayed Data from NSDQ)

$5.82 USD

5.82
1,382,825

+0.19 (3.37%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.82 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 26.67% and 14.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 28.28% and 16.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.75% and 12.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data

by Zacks Equity Research

The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.

TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids

by Zacks Equity Research

TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.

Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study

by Zacks Equity Research

Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans

by Zacks Equity Research

Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

by Zacks Equity Research

Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

by Zacks Equity Research

Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

by Zacks Equity Research

Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

by Zacks Equity Research

Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why

by Zacks Equity Research

SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now

by Zacks Equity Research

Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

by Zacks Equity Research

Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 5.71% and 0.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Adaptive Biotechnologies (ADPT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.